|
|
|
Volumn 29, Issue SUPPL. 65, 2002, Pages 39-43
|
|
Preventing joint damage as the best measure of biologic drug therapy
|
|
Author keywords
Anakinra; Cytokines; Joint erosion; Rheumatoid arthritis
|
|
Indexed keywords
ETANERCEPT;
INFLIXIMAB;
INTERLEUKIN 1;
METHOTREXATE;
RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
TUMOR NECROSIS FACTOR ALPHA;
ANTIRHEUMATIC AGENT;
BIOLOGICAL PRODUCT;
CYTOKINE;
IL1RN PROTEIN, HUMAN;
INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
MONOCLONAL ANTIBODY;
SIALOGLYCOPROTEIN;
ARTICLE;
DRUG EFFICACY;
HUMAN;
IMMUNOMODULATION;
IMMUNOTHERAPY;
JOINT INJURY;
OUTCOMES RESEARCH;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
ARTHROPATHY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DISEASE COURSE;
DRUG EFFECT;
FEMALE;
HOSPITALIZATION;
JOINT CHARACTERISTICS AND FUNCTIONS;
MALE;
METABOLISM;
PAIN ASSESSMENT;
PHYSIOLOGY;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
BIOLOGICAL PRODUCTS;
CYTOKINES;
DISEASE PROGRESSION;
FEMALE;
HUMANS;
INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN;
JOINT DEFORMITIES, ACQUIRED;
MALE;
PAIN MEASUREMENT;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIALS;
RANGE OF MOTION, ARTICULAR;
SEVERITY OF ILLNESS INDEX;
SIALOGLYCOPROTEINS;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 0036732029
PISSN: 0315162X
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (22)
|
|
References (16)
|
